207 related articles for article (PubMed ID: 32723601)
21. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab.
Zhang X; Song K; Tong F; Fei M; Guo H; Lu Z; Wang J; Zheng C
Blood Adv; 2020 Apr; 4(7):1307-1310. PubMed ID: 32243501
[TBL] [Abstract][Full Text] [Related]
22. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
Zhang Y; Zhong Y; Pan L; Dong J
Drug Discov Ther; 2020; 14(2):100-102. PubMed ID: 32378647
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
[TBL] [Abstract][Full Text] [Related]
24. Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19.
Nakamura H; Miyagi K; Otsuki M; Higure Y; Nishiyama N; Kinjo T; Nakamatsu M; Haranaga S; Tateyama M; Fujita J
Intern Med; 2020 Nov; 59(22):2945-2949. PubMed ID: 32963155
[TBL] [Abstract][Full Text] [Related]
25. Thoughts on COVID-19 and autoimmune diseases.
Askanase AD; Khalili L; Buyon JP
Lupus Sci Med; 2020; 7(1):e000396. PubMed ID: 32341791
[TBL] [Abstract][Full Text] [Related]
26. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
[TBL] [Abstract][Full Text] [Related]
27. Vascular microthrombosis associated with increased interleukin-6. A severe acute respiratory distress syndrome in COVID-19 patients treated with tocilizumab.
Mohebbi N; Abedini A; Lashgari R; Razavi F; Varahram M; Kiani A
Adv Respir Med; 2020; 88(5):468-469. PubMed ID: 33169824
[No Abstract] [Full Text] [Related]
28. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
[No Abstract] [Full Text] [Related]
29. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19.
Moutsopoulos HM
Ann Rheum Dis; 2020 Sep; 79(9):1253-1254. PubMed ID: 32345616
[No Abstract] [Full Text] [Related]
30. Successful treatment with Remdesivir and corticosteroids in a patient with COVID-19-associated pneumonia: A case report.
Gonzales-Zamora JA; Quiroz T; Vega AD
Medwave; 2020 Aug; 20(7):e7998. PubMed ID: 32876623
[TBL] [Abstract][Full Text] [Related]
31. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
Miao Y; Fan L; Li JY
Front Immunol; 2020; 11():1445. PubMed ID: 32612616
[No Abstract] [Full Text] [Related]
32. COVID-19 in a Patient With Rheumatoid Arthritis During Tocilizumab Treatment.
Yamada Z; Nanki T
J Clin Rheumatol; 2020 Sep; 26(6):240-241. PubMed ID: 32732527
[No Abstract] [Full Text] [Related]
33. Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.
Coskun Benlidayi I; Kurtaran B; Tirasci E; Guzel R
Rheumatol Int; 2020 Oct; 40(10):1707-1716. PubMed ID: 32591970
[TBL] [Abstract][Full Text] [Related]
34. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
[TBL] [Abstract][Full Text] [Related]
35. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.
Muhović D; Bojović J; Bulatović A; Vukčević B; Ratković M; Lazović R; Smolović B
Liver Int; 2020 Aug; 40(8):1901-1905. PubMed ID: 32478465
[TBL] [Abstract][Full Text] [Related]
36. A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis.
Mazza S; Sorce A; Peyvandi F; Vecchi M; Caprioli F
Gut; 2020 Jun; 69(6):1148-1149. PubMed ID: 32245909
[No Abstract] [Full Text] [Related]
37. Treatment considerations for patients with pemphigus during the COVID-19 pandemic.
Shakshouk H; Daneshpazhooh M; Murrell DF; Lehman JS
J Am Acad Dermatol; 2020 Jun; 82(6):e235-e236. PubMed ID: 32283243
[No Abstract] [Full Text] [Related]
38. Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.
Gautier-Vargas G; Baldacini C; Benotmane I; Keller N; Perrin P; Moulin B; Caillard S
Kidney Int; 2020 Aug; 98(2):508-509. PubMed ID: 32505467
[No Abstract] [Full Text] [Related]
39. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.
Ceribelli A; Motta F; De Santis M; Ansari AA; Ridgway WM; Gershwin ME; Selmi C
J Autoimmun; 2020 May; 109():102442. PubMed ID: 32253068
[TBL] [Abstract][Full Text] [Related]
40. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
